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Brief communication
Salivary  2-microglobulin  positively  correlates
with ESSPRI  in patients  with  primary  Sjögren’s
syndrome
A  2-microglobulina  salivar  se  correlaciona  positivamente  com  o
ESSPRI  em  pacientes  com  síndrome  de  Sjögren  primária
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with pSS were enrolled. Those with history of HIV, hepati-Available online 14 December 2016
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune
disorder largely distinguished by lymphocytic exocrinopathy.1
Salivary and lachrymal glands are mainly impaired in pSS.
Saliva is therefore considered an optimal biological ﬂuid that
closely reﬂects the underlying autoimmune exocrinopathy.1,2
For instance, in those with pSS, 2-microglobulin (B2M)
is increased in whole saliva.2 This protein is signiﬁcantly
correlated with lymphocytic inﬁltration in labial salivary
glands.3 The EULAR Sjögren’s syndrome Patient Reported
Index (ESSPRI) is a patient-centered measure of symptoms.
This index has been recently shown to be valid, reliable
and sensitive to change in a large cohort of patients with
pSS.1 The ESSPRI correlated signiﬁcantly with serum B2M in
patients with pSS.4 However, serum and salivary levels of
B2M were not correlated in a previous study.5 It is currently
unknown whether the ESSPRI is also correlated with salivary
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licenses/by-nc-nd/4.0/).B2M in those with pSS. This is of particular importance since,
if these two parameters are indeed associated, a treatment
which could decrease inﬂammatory activity would improve
the patients’ symptoms, and also because the treatment of
chronic diseases ﬁnally aims to improve quality of life and
patient-perceived health status.6 Due to the above issues, this
study was conducted. Salivary B2M was further subanalysed
according to the patient-acceptable symptom state (PASS).
A cut-off value for salivary B2M to distinguish those who
were above the threshold of unsatisfactory symptom state
(ESSPRI ≥ 5) was also determined.
In this observational study, adult patients (≥18-year-old) (G. Delgado-García).
tis B and C, head and neck radiation therapy, sarcoidosis,
amyloidosis, chronic kidney disease, lymphoma, or multi-
ple myeloma were excluded. pSS was diagnosed according to
e under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1 – A signiﬁcant positive correlation between the
ESSPRI and salivary B2M was found (Kendall’s tau 0.759,
and patients’ symptoms (ESSPRI) did not correlate.6,13 Hence,
these two indexes complement each other in the evaluation
of patients with pSS.1
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Fig. 2 – ROC curve analysis for salivary B2M. It showed an
area under the curve of 0.965 (95% CI 0.891–0.994,r e v b r a s r e u m a t o l
he American College of Rheumatology (ACR)/Sjögren’s Inter-
ational Collaborative Clinical Alliance (SICCA) criteria.7 All
atients completed the ESSPRI. This index is a mean score
f 0–10 numerical scales for pain, fatigue and dryness fea-
ures (including oral, ocular and global dryness).1 PASS was
eﬁned as the value beyond which patients consider them-
elves well (i.e., ESSPRI < 5).6 The degree of histopathological
hange was assessed using the grading standard for labial sali-
ary gland biopsy.8 Written informed consent was obtained
rom all patients, and the study was approved by the local
thics committee.
Our study protocol was similar to that described previously
y Castro et al.5 Saliva samples were collected over 15 min  by
assive spitting into containers. Unstimulated whole saliva
amples were centrifuged at 14,000 × g for 20 min  at +4 ◦C
rior to assaying. B2M was determined by an enzyme-linked
mmunosorbent assay (Abcam, Cambridge, UK) and results
ere expressed as nanograms per milliliter (ng/mL). This
ssay was performed according to the manufacturer’s instruc-
ion manual.
Normality of data distribution was assessed using the
hapiro–Wilk test. The measurement of the strength of the
ssociation between the variables was explored using the
endall’s correlation coefﬁcient. Continuous variables were
ompared between groups with the Mann–Whitney U test. A
eceiver operating characteristic (ROC) curve was generated to
etermine the cutoff value in the B2M with the highest level of
ccuracy in identifying patients with unsatisfactory symptom
tate (ESSPRI ≥ 5). Sensitivity and speciﬁcity were thus calcu-
ated. Unless indicated otherwise, all results are expressed
s mean ± standard deviation or median (interquartile range).
tatistical analyses were conducted using SigmaStat (v. 3.5,
rkrath, Germany) or MedCalc (v. 14.12.0, Ostend, Belgium),
nd a p-value below 0.05 (p < 0.05) was considered signiﬁcant.
We included 71 consecutive female patients with pSS aged
3.05 ± 12.19 years. They had sicca syndrome for 48 (24–81)
onths. In our patients, the median ESSPRI was 6.3 (3.3–8.6),
hile the median B2M was 0.671 (0.284–1.072) ng/mL. A signiﬁ-
ant positive correlation between ESSPRI and salivary B2M was
ound (0.759, 95% CI 0.656–0.837, p < 0.0001) (Fig. 1). The degree
f histopathological change was not signiﬁcantly correlated
ith salivary B2M (0.0485, 95% CI −0.123 to 0.237, p = 0.55). Data
ere then subanalysed into PASS (n = 28) and non-PASS groups
n = 43). Salivary B2M was comparatively higher in those who
ere above the threshold of unsatisfactory symptom state
0.878 [0.682–1.263] vs 0.219 [0.10–0.324] ng/mL, p < 0.0001). The
OC curve analysis for salivary B2M showed an area under the
urve of 0.965 (95% CI 0.891–0.994, p < 0.0001) with an optimal
utoff value of 0.472 ng/mL (Fig. 2). Sensitivity and speciﬁcity
ere 97.67% and 96.30%, respectively.
B2M is a nonglycosylated low-molecular-weight protein,
hich is part of the major histocompatibility complex I
nd is particularly expressed in lymphocytes. This protein
s regulated by interferon and, in turn, this pathway acti-
ation is thought to be related to the disease progression
f pSS.9,10 The increased expression of B2M in whole saliva
ight thus represent both systemic B cells activation andncreased intraglandular immunoglobulin synthesis, which
re peculiar facets of pSS.10,11 As noted before, the ESSPRI
as been validated recently in an international multicenter95% CI 0.656–0.837, p < 0.0001).
cohort of patients with pSS. Two Spanish-speaking countries
were included in the latter study (including one from Latin
America).1 The ESSPRI has been also validated into Brazilian
Portuguese.12 The median ESSPRI in our study is similar to that
already described by Seror et al. in their international multi-
center study.1 The PASS is similar to the concept of low-disease
activity for the EULAR SS disease activity index (ESSDAI; i.e.,
ESSDAI < 5). Nevertheless, these two indexes did not necessar-
ily overlap, particularly in pSS where disease activity (ESSDAI)p < 0.0001) with an optimal cutoff value of 0.472 ng/mL.
Sensitivity and speciﬁcity were  97.67% and 96.30%,
respectively.
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Our results support the notion that salivary B2M might act
as a biomarker for an unsatisfactory symptom state (Fig. 2).
Patients with systemic features have higher scores on ESSPRI,
which means that they are more  symptomatic.1 Addition-
ally, a signiﬁcant association between salivary B2M (measured
by enzyme-linked immunosorbent assay) and serum anti-
Ro/SSA antibodies has been previously reported.11 This is
relevant because, in patients with pSS, these antibodies are
likely to be strongly involved in the clinical severity of ker-
atoconjunctivitis sicca,14 and also because higher levels of
these antibodies have been reported in patients with sys-
temic features (e.g., purpura).15 Therefore, considering these
two ﬁndings together, higher concentrations of salivary B2M
may also distinguish those with systemic features, who could
beneﬁt most from treatment.6
In summary, there is a signiﬁcant positive correlation
between the ESSPRI and salivary B2M. In addition, salivary
B2M is comparatively higher in those who were above the
threshold of unsatisfactory symptom state. Our results sug-
gest that, in pSS, the intensity of the symptoms is indeed
associated with sB2M. sB2M might thus represent a simple and
objective method to aid in the identiﬁcation of those with an
unsatisfactory symptom state. The latter is especially impor-
tant in chronic diseases, such as pSS, since their treatment
aims to improve patients’ quality of life.
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